HALISTER1: Amicus Therapeutics Jumps 8.6% Pre-Market After Baird Upgrade

Amicus Therapeutics Jumps 8.6% Pre-Market After Baird Upgrade

(Bloomberg) -- Amicus rose to $5.80-share on 50.9k shares after Baird analyst Michael Ulz upgraded to outperform from neutral and raised PT to $10 from $7 on pipeline upside potential.
  • Says the U.S. regulatory path forward for Galafold "is now clear with a GI study," expected to begin in 2017; full approval likely in 2020
  • Says SD-101 offers near-term upside potential with Phase 3 data expected mid-2017; positive results would provide >$ 5-$6 boost
  • Additional updates on the Pompe program could drive upside
  • FOLD has 6 buys, 1 hold, 0 sells with avg PT $11
  • NOTE: Nov. 29: Amicus Chance of Galafold Success Higher After Delay: Chardan
To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.net
Alert: HALISTER1
Source: BFW (Bloomberg First Word)

Tickers
FOLD US (Amicus Therapeutics Inc)

People
Michael Ulz (Robert W Baird & Co Inc)

To de-activate this alert, click here

UUID: 7947283